Skye Bioscience, Inc. has hired Chris Twitty, PhD, as the Company's first chief scientific officer (CSO). With over 25 years of life science research and drug development experience, he will be a key member of Skye's executive team with responsibility for leading the strategic development of Skye's scientific estate. Dr. Twitty has led R&D and translational efforts to expand drug pipelines and supported multiple IND filings for novel therapeutics.

He has additionally contributed to CMC, non-clinical, regulatory and clinical development efforts necessary to initiate clinical trials. He has significant experience in biomarker discovery and clinical biomarker strategies. Dr. Twitty was most recently CSO at Onchilles Pharma.

Prior to that he was Director and Head of Clinical Sciences and then VP of R&D and CSO at Oncosec Medical. He began his career at Bayer and also worked in research at Cell Genesys and Tocagen. Dr. Twitty has a PhD Molecular Microbiology and Immunology from Oregon Health Sciences University and completed his post-doctoral training with Dr. Bernard Fox at the Earle A. Chiles Research Institute.

He is a co-author of 19 publications and a named inventor on three patents.